Search Results
Your search for The A matches 31896 pages
Showing 4401 - 4450Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is part ...
Dual Checkpoint Inhibitor Therapy Elicits Responses in Highly Mutated Breast Cancer
Patients with advanced HER2-negative metastatic breast cancer and high tumor mutational burden achieved responses—often durable—from treatment with the immunotherapy doublet of nivolumab and ipilimumab, according to results of the phase II NIMBUS trial reported at the 2021 San Antonio Breast Cancer ...
Expert Point of View: Mark E. Robson, MD
“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...
OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer
The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer
Use of the first investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly reduced the risk of death or disease progression and lengthened progression-free survival compared with standard-of-care endocrine therapy with fulvestrant or an aromatase inhibitor in...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Long-Term Follow-up of monarchE: Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer
Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy in the adjuvant treatment of early high-risk hormone receptor–positive, HER2-negative breast cancer, regardless of Ki67 index. The latest findings were reported at a ...
Researchers Discover Predictive Biomarker of Response to Therapy in Patients With Microsatellite-Stable Metastatic Colorectal Cancer
Researchers have unmasked mutations in the RNF43 gene as predictive biomarkers of a response to treatment with anti-BRAF/EGFR combination therapy in patients with microsatellite-stable BRAF V600E–mutated metastatic colorectal cancer. Data showed that patients with tumors harboring loss-of-function...
Long-Term Outcomes With Minimal-Access vs Conventional Breast Surgery in Stage 0 to III Breast Cancer
In a Chinese single-center, retrospective cohort, propensity score–matched analysis reported in JAMA Surgery, Wan et al found no difference in long-term outcomes, including distant metastasis–free and overall survival, with minimal-access breast surgery vs conventional breast surgery in women with...
Computer Platform May Help Match Patients With Cancer to Targeted Therapy Trials
As more patients with cancer have their tumors genomically profiled and more therapies targeting genomic alterations enter clinical trials, the task of connecting patients with trials for which they are eligible can be especially challenging. The novel computer platform MatchMiner, developed by the ...
Recent FDA Approvals in Breast Cancer
In the past year, the U.S. Food and Drug Administration (FDA) approved four treatment options for patients with breast cancer, which are summarized herein. T-DXd for HER2-Low Breast Cancer On August 5, 2022, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) for adult patients with...
Polycystic Ovary Syndrome and Risk of Pancreatic Cancer
In a single-center case-control study reported as a research letter in JAMA Oncology, Peeri et al found that women with polycystic ovary syndrome (PCOS) may be at an increased risk of developing pancreatic cancer. Study Details The study involved data from the Memorial Sloan Kettering Cancer Center ...
Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma
In a Chinese single-center phase II trial reported in JAMA Surgery, Wu et al found neoadjuvant intensity-modulated radiotherapy (IMRT) followed by hepatectomy could be an effective treatment option in patients with centrally located hepatocellular carcinoma. Study Details In the study, 38 patients...
Risk of Meningioma in Childhood Cancer Survivors
In a pooled analysis reported in JAMA Oncology, Withrow et al found that increased exposure of the meninges to radiation therapy was associated with an increased risk of developing meningioma in survivors of childhood cancer. Receipt of methotrexate was also associated with increased risk. Study...
Palliative Care Use Among Commercially Insured U.S. Patients With Metastatic Cancer: 2001–2016
In a study reported in JCO Oncology Practice, Ferrario et al found that while use of palliative care among commercially insured patients aged 25 to 64 years in the United States with metastatic cancer has increased since 2001, use remained at 40% among patients with very poor–prognosis cancers in...
Association of Autoantibodies to Gastric Mucosa and Risk of Gastric Cancer
In a case-control study reported in JAMA Oncology, Minkyo Song, MD, PhD, and colleagues found that seropositivity for gastric antiparietal cell antibodies (APCAs) was associated with an increased risk of gastric cancer among younger Finnish women who were seronegative for antibodies to Helicobacter ...
S.M. Qasim Hussaini, MD, on Colon Cancer Treatment Outcomes and Historical Housing Discrimination
S. M. Qasim Hussaini, MD, of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, discusses findings from a nationwide study of the association between living in areas with discriminatory mortgage practices from the 1930s with present-day access to quality colon cancer care. The...
Effect of Social Factors on Cancer Screening Rates Across U.S. Counties
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
Mediterranean Diet May Improve Immunotherapy Response Rates and Progression-Free Survival in Advanced Melanoma, New Study Suggests
Following a Mediterranean diet rich in fiber, monounsaturated fatty acids, and polyphenols may be associated with improved immunotherapy response rates and progression-free survival in patients with advanced melanoma, according to a recent study presented at the United European Gastroenterology...
Study Analyzes Postimaging Diagnoses of Pancreatic Cancer
Computed tomography (CT) and magnetic resonance imaging (MRI) scans may miss the detection of some pancreatic cancer tumors, narrowing the window for life-saving curative surgery, according to new research presented at the United European Gastroenterology (UEG) Week 2022 (Abstract OP192). The...
Letrozole/Abemaciclib for Estrogen Receptor–Positive Recurrent Endometrial Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Panagiotis A. Konstantinopoulos, MD, PhD, and colleagues found that letrozole plus abemaciclib produced activity in patients with estrogen receptor (ER)-positive recurrent endometrial cancer. Study Details In the study, 30 patients...
Eligibility for Lung Cancer Screening Among Women With a Smoking History Undergoing Breast Cancer Screening
In a single-center retrospective cohort study reported in JAMA Network Open, Titan et al identified the proportion of women with a history of smoking undergoing breast cancer screening with mammography who were eligible for low-dose computed tomography (CT) lung cancer screening, as well as the...
Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer
In a phase Ib/II study reported in the Journal of Clinical Oncology, Christopher J. Hoimes, MD, and colleagues found that first-line enfortumab vedotin-ejfv plus pembrolizumab produced a high response rate and prolonged response durations in cisplatin-ineligible, previously untreated patients with...
Switch to Fulvestrant/Palbociclib With Rising ESR1 Mutation Level in Blood During Aromatase Inhibitor/Palbociclib Therapy in Patients With Advanced Breast Cancer
As reported in The Lancet Oncology by François-Clément Bidard, MD, and colleagues, the French phase III PADA-1 trial has shown that switching to fulvestrant/palbociclib vs continuing first-line aromatase inhibitor (AI)/palbociclib therapy was associated with improved progression-free survival among ...
Deaths Attributed to Both Cancer and COVID-19 in the United States: March to December 2020
In a research letter published in JAMA Oncology, Xuesong Han, PhD, and colleagues identified the number of deaths attributable to both cancer and COVID-19, with either as an underlying or contributing cause, in the United States from March 1 to December 31, 2020, and analyzed risk factors for these ...
Expert Point of View: James Larkin, PhD and Andrea Cercek, MD
Invited discussant James Larkin, PhD, a clinical researcher at the Royal Marsden Hospital, London, commented on the findings from NICHE-2.1 “These striking data are consistent with the recent report in locally advanced mismatch repair–deficient [dMMR] rectal cancer from Memorial Sloan Kettering.2...
C-Reactive Protein Level and Cognitive Function in Breast Cancer Survivors Aged 60 and Older
As reported in the Journal of Clinical Oncology by Carroll et al, an analysis from the Thinking and Living with Cancer Study has shown higher levels of C-reactive protein (CRP) at baseline and during follow-up among women with stage 0 to III breast cancer diagnosed at age ≥ 60 years vs controls,...
NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer
Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...
Oncologist Participation in Medicare OCM and Patient Receipt of Novel Therapies
In a study reported in JAMA Network Open, Christopher R. Manz, MD, MSHP, and colleagues found that oncologist participation in the Medicare Oncology Care Model (OCM) was not associated with a reduced likelihood of prescribing novel cancer therapies to their patients. As stated by the investigators, ...
Financial Hardship and Risk Factors in Patients With Cancer Receiving Routine Clinical Care
In a study reported in JCO Oncology Practice, Voleti et al identified the proportion of patients with cancer receiving routine clinical care who reported financial hardship and analyzed risk factors for financial hardship. The researchers found that patients who reported experiencing financial...
Nivolumab/Ipilimumab vs Dabrafenib/Trametinib With Switch at Disease Progression for Metastatic BRAF-Mutant Melanoma
As reported in the Journal of Clinical Oncology by Michael B. Atkins, MD, and colleagues, the phase III DREAMseq trial (ECOG-ACRIN EA6134) showed that first-line treatment with nivolumab plus ipilimumab followed at disease progression with dabrafenib and trametinib improved 2-year overall survival...
Impact of CDC Opioid-Prescribing Guideline on Prescriptions and Potential Misuse/Substance Use Disorder Among Childhood Cancer Survivors
In a study reported in JAMA Oncology, Hu et al found decreases in the rates of opiate prescription and potential misuse/substance use disorders among survivors of childhood cancer following the March 2016 release of the Centers for Disease Control and Prevention (CDC) opioid-prescribing guideline....
Treatments and Outcomes for Locally Advanced Rectal Cancer in Patients Aged 80 and Older
In an analysis of National Cancer Database data reported in JAMA Surgery, Nassoiy et al found that neoadjuvant chemoradiation therapy followed by surgery was associated with higher rates of R0 resection and improved survival vs other treatments in patients aged 80 and older undergoing surgery for...
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
Real-World Cost of Care for Pediatric ALL Among Commercially Insured Patients
In a study reported in JCO Oncology Practice, Lucie M. Turcotte, MD, MPH, and colleagues found that real-world costs for care for commercially insured U.S. pediatric patients with acute lymphoblastic leukemia (ALL) were higher in those diagnosed at age 10 or older and have increased substantially...
Study Finds Cost of Cancer Care May Impact Health of Low-Income Survivors
The cost of cancer treatment may negatively impact the physical and mental health of survivors who are living in poverty, according to a recent study published by Coughlin et al in the Journal of Oncology Practice. The findings provide important information about the impact social determinants may...
Decrease in Breast Cancer Mortality Rate Continues, but Gap Persists for Black Women: From American Cancer Society Report
Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...
ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer Updated to Reflect New Trastuzumab Deruxtecan Data
Just 1 month after the DESTINY-Breast04 data were presented at the 2022 ASCO Annual Meeting Plenary Session,1 an ASCO expert panel released updated guidance that endorses the adoption of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) into clinical practice for patients with...
Cancer Care and Reproductive Health Resources for the Oncology Community
On June 24, 2022, the U.S. Supreme Court announced its decision in Dobbs v Jackson Women’s Health Organization, effectively eliminating the constitutional right to abortion and returning the power to regulate reproductive health to individual states. Some states have already taken action to...
ASCO and the African Organisation for Research and Training in Cancer Announce Innovative Collaboration to Advance Cancer Research in Africa
ASCO and the African Organisation for Research and Training in Cancer (AORTIC) have signed a memorandum of understanding (MOU) committing the two organizations to collaborate to advance cancer research in Africa. Harnessing the respective programs, leaders, and member networks of both...
Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, 2022, ibrutinib was approved for pediatric patients 1 year of age or older with chronic graft-vs-host disease after failure of one or more lines of systemic therapy.1 A new oral suspension formulation is available. Supporting Efficacy Data Approval was based on findings from the...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Vanderbilt University Medical Center Selects New Director of the Division of Infectious Diseases
Kelly Dooley, MD, PhD, MPH, has been appointed Addison B. Scoville Jr. Professor of Medicine and Director of the Division of Infectious Diseases in the Department of Medicine at Vanderbilt University Medical Center (VUMC). Dr. Dooley comes to Vanderbilt from The Johns Hopkins School of Medicine in...
Expert Point of View: Jonathan Ledermann, MD
Jonathan Ledermann, MD, of UCL Cancer Institute University College London, was the formal discussant of both the phase III SOLO1 and PAOLA-1 trials. He was quite enthusiastic about SOLO1: “Perhaps, this is really cure we are seeing.” He also noted that overall survival is still immature and is...
First-Line Maintenance With Olaparib Improved Overall Survival in Subsets of Patients With Advanced Ovarian Cancer in Two Phase III Trials
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD
TROPiCS-02 is a statistically positive trial, with the primary endpoint met and also now with an overall survival gain of 3.2 months,” said the study’s invited discussant Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology, Barcelona. “TROPiCS-02 is...
TROPiCS-02: Sacituzumab Govitecan Improves Overall Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in women with previously treated, hormone receptor–positive/HER2-negative, locally recurrent, inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial.1 The...
Expert Point of View: Mary O’Brien, MD
Formal discussant of the KEYNOTE-189 and KEYNOTE-407 trials, Mary O’Brien, MD, Head of the Lung Unit, Royal Marsden Hospital, NHS Foundation Trust, London, found that both studies showed consistent gains in overall and progression-free survival with pembrolizumab/chemotherapy, but she expressed...
5-Year Follow-up Supports Survival Benefit of Pembrolizumab Plus Chemotherapy in Squamous and Nonsquamous NSCLC
Pembrolizumab (anti–PD-1 therapy) plus chemotherapy continued to demonstrate a survival benefit and durable responses as first-line treatment of metastatic non–small cell lung cancer (NSCLC), according to the results of two phase III trials.1,2 Five-year overall survival was improved in both...
